Trial
NCT04179110
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
—
Condition
Transitional Cell Carcinoma
Intervention
Pembrolizumab and Ramucirumab
Why stopped
Funding was withdrawn prior to first enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-22